Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS-101: HS-20093 Combinations in Solid Tumors
NCT06332170Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Apr 2024
- Primary completion
- May 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of risvutatug rezetecan in solid tumor (5 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose. Started Apr 2024; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06332170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06332170.